CRO had 12 registrations equaling 8.875 credits this month. This ends our second NCORP grant year. Yearly statistics are being gathered and will be shared in our CRO annual report being compiled at this time.

**CRO Website Update**
CRO’s updated website went live on 7/27/16. Our website now includes trial schemas and eligibility criteria, a new patient education component and has a brighter look. Here is the link to our updated website [http://ozarks cancerc research.org/](http://ozarks cancerc research.org/) Please take a look.

**CRO Marketing**
Marketing departments at CoxHealth and Mercy Springfield are working with CRO to produce marketing material for 30-sec TV and Radio ads. Our goal is to educate our community regarding CRO services and thus increase trial enrollments.

**Dr. John Bumberry Co-Author**
CRO investigator, John Bumberry will be a co-author for EA study E4112 - Prospective Study of Magnetic Resonance Imaging (MRI) and Multiparameter Gene Expression Assay in Ductal Carcinoma in Situ. Cancer Research for the Ozarks entered 15 patients and is entitled to an accrual author. Dr. Bumberry placed eight of CRO’s enrolled fifteen patients on the trial. Congratulations Dr. Bumberry!!

**Tissue + Blood NCI Administrative Supplement**
CRO has submitted a grant request to NIH to participate in “PDX Supplement, Tissue + Blood (v3)” for the upcoming grant year 2016-2017. This procurement opportunity includes the collection of 36 paired tissue + blood submissions. We are eager to receive NIH’s response.

**Study Profile**
E3612 “A Randomized Phase II Trial of Ipilimumab with or without Bevacizumab in Patients with Unresectable Stage III or Stage IV Melanoma” is this month’s profile study. The purpose of this research study is to compare the effects, good and/or bad, of ipilimumab or in combination with bevacizumab in treating unresectable advanced melanoma. Ipilimumab is the standard treatment for advanced melanoma and it does a good job in treating melanoma (skin cancer). Bevacizumab is an angiogenesis inhibitor, a drug that slows the growth of new blood vessels. It is approved by the U.S. Food & Drug Administration (FDA) for treatment of other cancers but it’s use in this study is experimental. This study is looking to see if the addition of bevacizumab to ipilimumab can further
improve treatment of melanoma. Participants must have unresectable (can't be removed surgically) advanced melanoma that has not been treated or has only received one treatment.  

**Judy Hancock** is our Cancer Care Delivery Research Coordinator. Judy has been a practice manager for the past 22 years, most recently at Dr. Carlson’s office. She is a licensed nursing home administrator. She holds a B.S. in Business Administration and a M.S. in Health Administration. We are very excited to have Judy join us on August 15, 2016.  

**Andrea Reaves**  
Andrea Reaves is our new regulatory coordinator. Andrea previously worked in research at Highlands Oncology Group in Fayetteville, Arkansas. Most recently she has worked at American National Insurance. Andrea will be with us at CRO on August 8th.  

**Swetha Mereddy**  
We are sad to have Swetha leave us at CRO but understand the strain her working in Springfield has been on her and her family who reside in Lincoln, Nebraska. Swetha’s last day with was July 29th. CRO’s Cancer Research Professional position is posted at both Cox & Mercy.  

**ACTIVATION OF CIRB Protocols:**  
None  

**ACTIVATION OF Local Protocols:**  
None  

**CIRB Protocols reactivated:**  
**ECOG-ACRIN EA1131** “A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy”  

**Closure through Local IRB:**  
**Alliance A091305** – Temporary suspension A Phase 2 Randomized Study of Efutuzazone, an Oral PPAR Agonist, in Combination With Paclitaxel Versus Paclitaxel in Patients With Advanced Anaplastic Thyroid Cancer  

**CIRB Closures:**  
**GOG-0281** “A Randomized Phase II/III Study To Assess The Efficacy of Trametinib (GSK 1120212) In Patients With Recurrent Or Progressive Low-Grade Serous Ovarian Cancer Or Peritoneal Cancer” - closed to accrual in US effective 6/29/2016  

**S1400C** Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer “ – **Arm C temporarily closed**”  

**CIRB Studies – Follow up terminated:**  
**NSABP B-38** “A Phase III, Adjuvant Trial Comparing Three Chemotherapy Regimens in Women With Node-Positive Breast Cancer: Docetaxel/ Doxorubicin/Cyclophosphamide (TAC); Dose-Dense (DD) Doxorubicin/Cyclophosphamide Followed by DD Paclitaxel (DD AC -> P); DD AC Followed by DD Paclitaxel Plus Gemcitabine (DD AC -> PG)”